Maxcyte (MXCT) Net Income towards Common Stockholders (2020 - 2026)

Maxcyte (MXCT) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$4.8 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 53.71% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$39.1 million, a 6.39% increase from a year earlier, with the FY2025 full-year figure at -$35.3 million, down 8.58% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$4.8 million, up from -$9.6 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for MXCT reached as high as -$4.8 million in Q1 2026 and fell as low as -$30.8 million in Q3 2022.
• Historically, Net Income towards Common Stockholders has averaged -$13.4 million across 5 years, with a median of -$10.6 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders plunged 1139.94% in 2022 and jumped 81.56% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$28.6 million in 2022, then soared by 81.56% to -$5.3 million in 2023, then slumped by 100.78% to -$10.6 million in 2024, then advanced by 9.45% to -$9.6 million in 2025, then soared by 50.5% to -$4.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$4.8 million in Q1 2026, -$9.6 million in Q4 2025, and -$12.4 million in Q3 2025.